We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Drugmakers and biotechnology firms have hundreds of products under development to treat roughly 150 diseases — all new products that are either in human clinical trials or under review by the FDA, according to a new survey by PhRMA.
Consumer advocacy organization Public Citizen is calling for a federal investigation into whether four nonprofit seniors groups received $41 million from PhRMA in 2002 to support candidates friendly to the pharmaceutical industry.
West Virginia lawmakers this month will consider adopting Australia’s method of determining drug prices in a first-of-its-kind move that could reward drugmakers for offering innovative products while forcing firms to charge the lowest price for products offering few new benefits.
PhRMA will establish a website for member companies to post clinical trial results for all marketed drug products in an effort to provide greater transparency of the clinical trial process, the trade group announced last week.
Aiming to provide greater transparency of the clinical trial process, PhRMA will establish a website for member companies to post clinical trial results for all marketed drug products, the trade group announced yesterday.
While Senate Majority Leader Bill Frist (R-Tenn.) has promised to bring drug importation legislation to the Senate floor this year, pharmaceutical industry observers say it is increasingly unlikely that lawmakers will pass such legislation before the end of the 108th Congress.
Under new formulary guidelines that favor lower-cost brands and generic products, the U.S. Air Force no longer will dispense some widely used, but expensive, brand pharmaceutical products.
According to at least one pharmaceutical analyst, the U.S. Pharmacopeia’s (USP’s) proposed guidelines for developing Medicare drug formularies could make it difficult for some brand products to make the cut.
The brand industry is urging the FDA to strengthen standards for FDC HIV/AIDS drugs, even as the FDA moves forward with approving the first once-daily fixed-dose combination (FDC) products and a leading generic FDC AIDS drug producer faces concerns about its products’ bioequivalency standards.